Australia Partners with OXB to Boost Gene Therapy Manufacturing

On March 18, 2026, the biotechnology world saw a major development as Oxford Biomedica (OXB), a global leader in cell and gene therapy, announced a five-year partnership with Australia’s Viral Vector Manufacturing Facility (VVMF).

This agreement is a significant step forward for the medical sector in the Asia-Pacific (APAC) region.

Under the deal, VVMF gains access to OXB’s proprietary inAAVate™ manufacturing platform, with the option to utilize the renowned LentiVector® technology in the future.

For VVMF, this collaboration is essential to accelerate its commercial readiness and bring advanced viral-vector manufacturing capabilities to Australia.

Meanwhile, for the UK-based OXB, the partnership serves as a strategic launchpad to expand its reach across the growing APAC market.

By establishing Australia as a regional hub for high-quality, scalable manufacturing, this agreement aims to reduce development risks and shorten timelines for companies creating life-saving therapies.

This move highlights the rising global demand for specialized manufacturing services and reinforces Australia's growing role in the international advanced therapeutics ecosystem.